RT Journal Article SR Electronic T1 PET Radiopharmaceuticals: What’s New, What’s Reimbursed, and What’s Next? JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 12 OP 16 DO 10.2967/jnmt.117.205021 VO 46 IS 1 A1 Bonnie N. Clarke YR 2018 UL http://tech.snmjournals.org/content/46/1/12.abstract AB The field of molecular imaging is undergoing a period of expansion. The number of radiopharmaceutical ligands, therapeutic isotope combinations, and targets continues to grow, with several new PET agents being approved over the last few years for diseases such as neuroendocrine tumor and prostate cancer. We will need to work together as a community to effectively use and advance these promising agents.